Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter

Sylvie Chalon, Hakan Hall, Wadad Saba, Lucette Garreau, Frédéric Dollé, Christer Halldin, Patrick Emond, Michel Bottlaender, Jean-Bernard Deloye, Julie Helfenbein, Jean-Claude Madelmont, Sylvie Bodard, Zoïa Mincheva, Jean-Claude Besnard and Denis Guilloteau
Journal of Pharmacology and Experimental Therapeutics April 2006, 317 (1) 147-152; DOI: https://doi.org/10.1124/jpet.105.096792
Sylvie Chalon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hakan Hall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wadad Saba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucette Garreau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frédéric Dollé
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christer Halldin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Emond
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Bottlaender
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Bernard Deloye
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Helfenbein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Claude Madelmont
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Bodard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zoïa Mincheva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Claude Besnard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Guilloteau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In the aim to develop an efficient fluorinated probe for positron emission tomography (PET) exploration of the dopamine transporter (DAT), we studied several in vitro and in vivo characteristics of the phenyltropane derivative (E)-N-(4-fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999). In vitro on rat striatal membrane, [3H]LBT-999 bound to a single site with a Kd of 9 nM, Bmax of 17 pmol/mg protein, and a very high selectivity for the DAT [IC50 for 1-{2-[bis-(4-fluorophenyl)-methoxy]ethyl}-4-(3-phenylpropyl)piperazine (GBR 12909) and (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane (PE2I): 2.4 and 18 nM, respectively; IC50 for paroxetine, citalopram, N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine, nisoxetine, and desipramine >1 μM]. In vitro on post-mortem human brain sections, LBT-999 bound with high intensity to the caudate-putamen, weakly to the thalamus, and not in the neocortex and cerebellum. This binding was totally abolished in the presence of PE2I. Ex vivo cerebral biodistribution of [11C]LBT-999 in rats showed striatum/cerebellum radioactivity ratios of 18 and 25 at 30 and 60 min postinjection, respectively. This accumulation was strongly prevented by preinjection of GBR 12909, whereas paroxetine and nisoxetine had no effect. An in vivo kinetic PET study in three baboons showed a fast and very high uptake in the striatum, with a plateau at 30 min postinjection and a maximal putamen/cerebellum ratio of 30. Taken together, these findings demonstrate that LBT-999 is a highly promising agent for in vivo exploration of the DAT. This probe is currently labeled with 18F for further characterizations.

Footnotes

  • This work was supported by the French “Réseau National de Technologies pour la Santé” under the RNTS 03B243 FLUOPARK program and by a grant from Biotechnocenter (Région Centre, France).

  • This study was funded in part by the EC-FP6 project Diagnostic Molecular Imaging (DiMI), LSHB-CT-2005-512146-3.

  • Partial results were presented as abstracts [Dollé F, Emond P, Saba W, Chalon S, Demphel S, Halldin C, Mavel S, Garreau L, Coulon C, Ottaviani M, et al. (2003) Radiosynthesis of [11C]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET, J Label Compd Radiopharm46:S145; and Hassoun W, Chalon S, Valette H, Dollé F, Garreau L, Emond P, Halldin C, Deloye J-B, Bottlaender M, and Guilloteau D (2004) [11C]LBT-999, a new radioligand to study the dopamine transporter with PET: preclinical characterization. Eur J Nucl Med31:28].

  • doi:10.1124/jpet.105.096792.

  • ABBREVIATIONS: DAT, dopamine transporter; FPCIT, N-3-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane; PET, positron emission tomography; FPCBT, N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-bromophenyl)nortropane; CFT, 2β-carbomethoxy-3β-(4-fluorophenyl)tropane; FPCT, 2β-carbomethoxy-3β-(4-chlorophenyl)-8-(3-fluoropropyl)nortropane; FECNT, N-2-fluoroethyl-2β-carbomethoxy-3β-(4-chlorophenyl)-nortropane; PE2I, (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane; LBT-999, (E)-N-(4-fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane; HPLC, high-performance liquid chromatography; MADAM, N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine; GBR12935, 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine; ID, injected dose; ROI, region of interest; GBR 12909, 1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine.

    • Received October 7, 2005.
    • Accepted December 5, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 387 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 387, Issue 1
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter

Sylvie Chalon, Hakan Hall, Wadad Saba, Lucette Garreau, Frédéric Dollé, Christer Halldin, Patrick Emond, Michel Bottlaender, Jean-Bernard Deloye, Julie Helfenbein, Jean-Claude Madelmont, Sylvie Bodard, Zoïa Mincheva, Jean-Claude Besnard and Denis Guilloteau
Journal of Pharmacology and Experimental Therapeutics April 1, 2006, 317 (1) 147-152; DOI: https://doi.org/10.1124/jpet.105.096792

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter

Sylvie Chalon, Hakan Hall, Wadad Saba, Lucette Garreau, Frédéric Dollé, Christer Halldin, Patrick Emond, Michel Bottlaender, Jean-Bernard Deloye, Julie Helfenbein, Jean-Claude Madelmont, Sylvie Bodard, Zoïa Mincheva, Jean-Claude Besnard and Denis Guilloteau
Journal of Pharmacology and Experimental Therapeutics April 1, 2006, 317 (1) 147-152; DOI: https://doi.org/10.1124/jpet.105.096792
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • M5 modulation of dopamine release in the striatum
  • Oxidative Stress and Nerve Agent Toxicity
  • PKA Is Responsible for the Presynaptic Inhibition by Xe
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics